Multiple sclerosis – new therapeutic directions

Paweł Łowiec¹, Piotr Trzonkowski², Kamil Chwojnicki¹

¹Department of Adult Neurology, Medical University of Gdańsk, Poland
²Department of Medical Immunology, Medical University of Gdańsk, Poland

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease which affects the central nervous system. Currently, there are numerous disease-modifying therapies for this condition. Most of them address the inflammatory aspects of the disease and are most effective in the relapsing-remitting stages of multiple sclerosis. However, none of them can completely stop the progression of MS and they are usually associated with adverse effects. There is an ongoing search for novel approaches that involve different modes of action. Here, we discuss examples of new immunomodulating agents such as antigen-specific therapies, neuroprotectants, regenerative strategies and gut microbiota modification.

Keywords: multiple sclerosis • neuroprotection • novel therapies • remyelination • gut microbiome

Citation

DOI: 10.31373/ejtcm/109612

Introduction

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating inflammatory and neurodegenerative disease that involves the central nervous system (CNS). It most commonly affects people between 20 and 40 years of age, predominantly women and it is a major cause of neurological disability among young adults. Most individuals with MS (85%) experience relapses/remissions during which rapid neurological worsening is followed by subsequent resolution of the symptoms. Unfortunately, after approximately 5-20 years the disease evolves into secondary-progressive phase, where the acute exacerbations are less frequent but there is a gradual neurological worsening overtime. A minority of patients develop a primary-progressive course of MS, with a constant increase in disability from the onset with no noticeable relapses [1].

MS has a multifactorial and complex pathogenesis with genetic and environmental factors involved [2-3]. The inflammation in CNS is driven by adaptive and innate immune system components [4]. Moreover, the-
re is a dysfunction of T-regulatory cells in people with MS. It is thought that peripheral failure of tolerance facilitates auto-reactive T-cell activation, possibly by an infectious agent through a mechanism of molecular mimicry. Although MOG, MBP, PLP and other molecules have been suggested, initiating target of the immune attack is still unknown. T-helper cells are shifted towards disease-promoting Th1 and Th17 populations and B-lymphocytes also take a part in MS pathology [5-6]. Destruction of myelin reveals new, previously sequestered neuroantigens, which become a target for the immune system, perpetuating continuous destruction in the CNS [7]. As the disease progresses there is less and less inflammatory activity. Patients still accumulate disability through gradual axonal loss due to neurodegeneration that dominates in the progressive phase of MS. Factors such as mitochondrial dysfunction, oxidative stress, intracellular ion imbalance, microglia activation may contribute to that process.

Currently, none of the available disease-modifying drugs (DMDs) arrest completely the disease or can be considered fully curative. Most of these therapies are immunosuppressive and turn down immune responses without appropriate specificity towards defined disease-associated autoantigens. Thus, novel therapies involve selective approaches that promise to affect only auto-reactive processes specific to MS [1]. This could not only enhance efficacy, but also reduce side effects. Many problems still persist in reestablishing immunotolerance such as route of administration of therapeutic agents, optimal dose and distribution to the CNS. Current options in progressive MS are limited because available therapies address mainly the inflammatory aspect of the disease. They do not concentrate on halting neurodegeneration nor do they aim to regenerate neural tissue that is already lost. Thus, there is an ongoing search for novel therapies. Here, some of the current strategies will be highlighted.

**Antigen specific approaches**

**Transdermal Myelin Antigens**

A promising approach is concentrated on induction of tolerance to specific auto-antigens by applying transdermal patches saturated with a mixture of myelin peptides: MOG 35-55 (myelin oligodendrocyte glycoprotein), MBP 85-99 (myelin basic protein) and PLP 139-151 (proteolipid protein) [8]. Patients with relapsing-remitting MS (RRMS) have been observed and compared to placebo. The treated individuals, have shown slower disability progression, less lesion accumulation and lower relapse rate [9]. Myelin peptides, administered at doses of 1mg and 10 mg transdermally, have induced a specific population of dendritic cells in the skin and local lymph nodes and promoted generation of Tr1 regulatory T-cells. As a result, weakened myelin-related immune responses have been observed. Transdermal treatment has caused an increase in IL-10 with concomitant decrease in TGF-beta and IFN-y secretion. Interestingly, the therapy did not affect the percentage of CD4+CD25+FoxP3+T-reg population [8]. Administration of transdermal myelin antigens proved to be safe with only mild local irritation of the skin reported [9].

**Tolerogenic Dendritic Cells**

Dendritic cells (DCs), not only process, present antigens and activate immune responses, but are also implied in tolerance induction. The main subpopulations of these cells are myeloid and plasmacytoid dendritic cells. Depending on the surrounding environment and maturation level they can be divided into immunogenic and tolerogenic. Tol-DCs are thought to induce tolerance via T-cells promoting their deletion, anergy or inducing a regulatory phenotype [10]. This knowledge has been translated into studies in animal model of MS called experimental autoimmune encephalitis (EAE). In these trials introduction of Tol-DCs coupled with myelin oligodendrocyte glycoprotein (MOG) has protected from induction or suppressed activity of the disease [11-13]. In one study Tol-DCs generated from RRMS patients and coupled with PLP induced selective hyporesponsiveness in autoreactive T-cells in-vitro [14]. Further trials are needed to assess feasibility of this approach in-vivo. Selective tuning of immune responses offers a lesser risk of adverse effects and perhaps greater efficacy. There are remaining questions about the best route of administration and selection of suitable myelin antigens in future studies that would apply tolerogenic dendritic cells [15].

**Autologous Myelin-Coupled PBMCs**

In ETIMS trial [16], induction of tolerance has been achieved through infusion of autologous peripheral blood mononuclear cells (PBMCs) coupled with selected myelin peptides in a group of RRMS and secondary progressive MS (SPMS) patients. Similar approach has been proven in experimental autoimmune encephalitis with amelioration of the disease in terms of occurrence and severity of relapses [17]. In the aforementioned human study, patients who have shown in-vitro responses to one of the seven epitopes of MOG, MBP and PLP have been enrolled. PBMCs were collected...
through leukapheresis and attached chemically to myelin peptides. Then, they were mixed with autologous plasma and administered intravenously to the patients. Participants were divided into two groups, one with low and the second with high disease activity. They received escalating doses of the product. Reduction of specific T-cell responses to auto-antigens has been reported in the higher dose group. The proposed mode of action is thought to be induction of anergy to specific autoreactive T-cells, apoptosis of coupled cells and subsequent phagocytosis by APCs expressing IL-10 and PD-L1 [17-19]. Induction of regulatory cells has been indicated, but only a slight increase has been measured. Importantly, no elevation in Th1 and Th17 populations has occurred, with treatment being generally safe.

**DNA and Peptide-based vaccination**

An approach where a modified DNA encoding altered human myelin-basic protein (MBP) altered with less immunologically stimulating motifs has been explored as a therapeutic vaccine [20-21]. In this case, it was administered intramuscularly in a cohort of SPMS and RRMS patients. Reduction of newly forming lesions was observed, but with no substantial effect on clinical progression. In response to vaccination, less IFN-γ secreting T-cells were produced and the levels of myelin-specific antibodies in the cerebrospinal fluid (CSF) decreased. Treatment was generally safe with no serious side effects. In another study, rather than DNA, introduction of TCR peptides from specific autoreactive T-cell clones has been used as a strategy [22-23]. They were administered either by intramuscular or intradermal route with addition of adjuvants to boost immunogenicity. The vaccine induced a subset of T-cells with subsequent reduction of responses to encephalitogens and secretion of IL-10 by these cells. Other proposed mechanism is related to an increased expression of FoxP3 in natural and inducible populations of T-regulatory cells [24]. Different approach used aptopes or short soluble peptides derived from naturally occurring MBP, which mimic processed epitopes [25-26]. After intradermal injection, they are bound to MHC-class II receptors on immature dendritic cells and are thought to induce specific T-regs. Risk profile was low. The therapy was safe with local skin reactions observed in a group of patients. Another trial [27] used mannosylated liposomes (CD-206) to facilitate re-uptake of immunodominant MBP peptides by dendritic cells which in turn should promote tolerance [28].

Not all efforts in peptide vaccination proved to be safe. Fear of disease exacerbation must be taken into account as evidenced by clinical worsening in patients who received altered MBP peptide ligand delivered subcutaneously [29].

**Attenuated Autologous T-cells**

A different cell vaccination technique involved the irradiation of myelin-autoreactive T-cells selected to be specific towards MBP, collected from the peripheral blood of individuals with RRMS and SPMS [30]. After that, autologous cells were reintroduced to the patients. A reduction of clinical and radiological activity of the disease was observed. The probable mode of action was an induction of specific cytotoxic T-cells against irradiated auto-reactive clones, which results in their deletion and selective suppression of autoimmune responses. Treatment has been safe with no general immunosuppression. Other trials with attenuated auto-reactive T-cells have been performed [31-33] with a wider repertoire of T-cells, auto-reactive not only to MBP. As in the first case, there were no serious adverse reactions.

**Regenerative therapies**

Prior therapeutic approaches targeted inflammatory processes that ultimately lead to demyelination and axonal loss. However, none of the above addressed possibilities of reversing the damage inflicted to the CNS during the course of MS. One avenue of research explores inhibition of molecules that contribute to myelin development suppression. LINGO-1 and AMIGO-3 are proteins which regulate neuroplasticity. LINGO-1 (Leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein 1) halts neurite outgrowth and mediates inhibitory effects on oligodendrocyte precursor maturation and therefore prevents axonal myelination. Other identified protein, AMIGO-3 (amphoterin-induced gene and open reading frame-3) exerts similar inhibitory effects as LINGO-1 [34]. Experimental blockade of LINGO-1 mediated signaling has shown benefits in animal models of CNS demyelination [35-36]. Human clinical studies gave mixed results. In the RENEW trial, Opicinumab (Li81 BilB033) an anti-LINGO-1 antibody were used to treat acute optic neuritis. Some benefits were observed in patients assessed with multifocal visual-evoked potential (MF-VEP) measurement [37-38]. Furthermore, the antibody was tested in the SYNERGY study, where its safety profile and influence on disability was compared to interferon-β therapy in SPMS and RRMS. Primary endpoint of the trial was not met. However, modest positive results with good risk profile were observed in intermediate dose subgroups [39-40].

Limited results from above studies could be explained by other mechanisms compensating for the loss of function by LINGO-1, therefore other therapeutic
targets are sought [34]. Another discovery are natural antibodies (NABs) directed towards CNS antigens and their remyelination-promoting subgroup [41-42]. One of them, rHlgM22 or recombinant human monoclonal IgM antibody-22, was used in EAE with positive effect on lesion load reduction and remyelination. Studies have shown that this antibody crosses the blood-brain barrier and exerts its effects without immunomodulation. It activates a signaling complex on oligodendrocyte precursor cells promoting their survival [43]. Presently, there are ongoing trials in MS, demonstrating its safe risk profile [44-45]. Other candidate for CNS repair is rHlgM12, reactive towards gangliosides and polysialic acid on neuronal surface, which promotes axonal growth [46]. Well known hormone, erythropoietin, induces remyelination and neuronal growth beyond its primary effects [47]. Although clinical benefit in small studies has been reported, larger trials have not proven efficacy in progressive MS [48-50].

Another approach is associated with multiple sclerosis-associated retrovirus (MSRV), which is a latent, endogenous virus, integrated into the genome. It can be reactivated in the course of EBV infection and the envelope protein (MSRV-env) has been found in CNS lesions of MS patients. As a Toll-like receptor-4 agonist, MSRV-env has been shown to have proinflammatory properties, preventing remyelination by inhibition of oligodendrocyte maturation [51]. GNbAC1 is a monoclonal antibody engineered to bind the envelope protein which indirectly suppresses neuroinflammation and favors myelin deposition. CHANGE-MS trial in RRMS [52] supports GNbAC1 effects on remyelination [53-55]. Small molecules could also have similar capabilities. Domperidone, a dopamine receptor antagonist, is being tested in SPM5 patients as prolactin released secondary to dopamine blockade, could improve remyelination [56-58].

Ocrelizumab has been approved in 2017 for the treatment of MS. This anti-CD20 monoclonal antibody is a breakthrough, because it is the first type of treatment that has been proven to show benefit in individuals with the primary progressive form of MS.

The success of monoclonal antibodies such as ocrelizumab and rituximab has led to further search for drugs with similar pharmacodynamics. Ofatumumab, an anti-CD20 humanized antibody, has been used in the treatment of chronic lymphocytic leukemia and rheumatoid arthritis [59-60]. As compared to rituximab, it binds to a different epitope resulting in a more pronounced complement-dependent cytotoxicity due to slower dissociation from the targeted antigen. As a result, profound B-cell depletion is noted. In phase II trial, ofatumumab has been administered intravenously to RRMS patients, with no increased risk of severe infections [61]. Ofatumumab has shown efficacy in reducing MRI markers of disease activity. Another placebo-controlled trial in RRMS patients explored a subcutaneous route of administration with good tolerance and comparable neuroimaging results [62].

Inebilizumab (MEDI-551) is a monoclonal antibody targeting CD19 receptor. It causes a rapid B-cell depletion similarly to the therapies directed against CD20(+) cells and immunologically translates to comparable effects. RRMS patients in phase I study, had slower lesion accumulation and acceptable risk [63]. BAFF or B-cell activating factor is a protein found both on B-lymphocyte membranes and in an unbound form. Its main function is a promotion of B-cell activation and survival. Located mainly on mature B-cells, BAFF is a target for tabalumab. Tested in patients with SLE and rheumatoid arthritis, it has shown effects on biological markers but with no clinical benefit. Acknowledging the role of B-cell mediated pathology in MS, tabalumab has been investigated as an option for patients with RRMS in a trial focused on safety and radiological activity markers, although with no reduction in new gadolinium-enhancing lesion formation [64].

**Cytokine targeting monoclonal antibodies**

The role of IL-17 and IL-12 has been implied in the pathophysiology of MS. T-lymphocytes that undergo differentiation to a Th17-phenotype are linked to neuroinflammation as their concentration correlates with disease severity in EAE. IL-17 activates microglia, macrophages and astrocytes, which secrete cytokines such as IL-6, TNF-a, IL-1 which in turn increase blood-brain barrier permeability and recruit more immune cells into the CNS. Enhanced myelin destruction and axonal loss occurs as a result [65]. IL-12 secreted by APCs in the CNS activates macrophages, B-cells, Th1...
cells and promotes inflammation. As in the periphery, this cytokine together with IL-23 differentiates naive T-cells into a Th17-subtype.

Ustekinumab is a monoclonal antibody targeted against the p40 subunit of IL-23 and IL-12 cytokines [66]. Studies using the EAE model have shown reduction in disease severity, however its efficacy has not been supported in human trials [67-69]. This discrepancy could be explained by low fraction of antibodies crossing the BBB, non-dependence from IL-23 signaling and disease compartmentalization to the CNS in the later stages of MS [70].

Secunikumab, a monoclonal antibody specific to IL-17A, aims to block the effects of this cytokine. Selective targeting of this interleukin is more beneficial than suppression of Th17 cells, because IL-17 can be secreted independently by δγT cells, astrocytes and oligodendrocytes in the CNS. There is the evidence that it could reduce radiological activity in patients with RRMS [71]. Risk of adverse effects has been acceptable with higher incidence of infections.

Tocilizumab approved for the treatment of resistant rheumatoid arthritis, is an antibody directed against IL-6, which promotes differentiation of naive T-cells towards Th17 subtype [72]. Blockage of this signaling has prevented the development of EAE. Unfortunately, tocilizumab has been associated with cases of new-onset MS in patients receiving the antibody for other indications, which raises concerns about its safety profile [73].

Aside from its proliferative properties, GM-CSF activates and recruits myeloid cells to the CNS during neuroinflammation and promotes their maturation [74]. MOR103 is a monoclonal antibody that interferes with GM-CSF on coupling to its receptor. As subsets of B-cells produce GM-CSF and contribute to MS pathology [75], MOR103 has become a potential treatment option in MS and recent trials have shown good tolerance of this drug [76].

**Neuroprotectants**

**Ion-channel blockers**

Experimental evidence has shown that the accumulation of sodium ions may lead to an increased intracellular calcium concentration. This activates signaling that can cause cell death. This mechanism can be referred to the neuronal loss seen in MS patients [77-78]. Ion channel blockade can reduce influx of sodium and thus lead to neuroprotection. Many antiepileptic drugs act as sodium-channel blockers and are being explored as a treatment in MS. Lamotrigine has been investigated in trials as a neuroprotectant with mixed results [79]. One study has not shown efficacy in reducing serum neurofilament concentrations in patients receiving lamotrigine, although subgroup analysis has suggested some benefit [80]. Phenytoin administered in acute optic neuritis has had a positive effect on retinal nerve fiber thickness measured using OCT [81]. Another trial using the EAE model supports the efficacy of oxcarbazepine [82]. It has been studied in SPMS patients in order to explore its neuroprotective properties (NCT02104661). Riluzole, a tetradotoxin-gated sodium channel blocker, is being tested in hope that it could prevent neurodegeneration in MS [83-84]. Further developments are ongoing as other agents share similar mode of action [85]. Amiloride, an acid-sensing sodium ion channel blocker, has been explored as a treatment in SPMS [83]. However, results in optic neuritis have been unsatisfactory [86].

**Inhibitors of microglia activation**

Microglial cells as a part of the innate immune system are thought to participate in destructive processes in the course of MS. Fluoxetine, aside from its antidepressant activity, also acts as a blocker of microglial-mediated inflammation. Furthermore, it has other beneficial effects such as up-regulating the expression of BDNF [87-88].

Laquinimod, which has undergone phase III trials, has not shown slower disability progression in lower doses (CONCERTO trial) in RRMS patients. Moreover, higher doses have been linked to unacceptable risk of cardiovascular events. Clinical studies in PPMS gave unsatisfactory results [89-90]. Pretreatment as well as administration in developed EAE caused reduced demyelination. Spinal cords and optic nerves of treated mice were infiltrated by phagocytes to a lesser extent in laquinimod treated groups. Human immune cells treated in-vitro also displayed decreased activation, thus suggesting the role of this mechanism in neurodegeneration [91-93].

Minocycline, an oral antibiotic from the tetracycline family, beyond antimicrobial activity, also exerts anti-inflammatory effects. It inhibits NMDA-mediated microglia activation in-vitro and it also promotes alternate anti-inflammatory differentiation of these cells in animal models of post-stroke neuroinflammation [94-95]. These effects could also be explored in MS and one study has shown a reduced risk of transformation from CIS to MS [96].

Ibudilast, an phosphodiesterase inhibitor, is a small molecule that crosses the blood-brain barrier. It acts as a neuroprotectant by inhibiting microglia activation...
and antagonism of macrophage-migration inhibitory factor. Furthermore, it also induces neurotrophin secretion [97-98]. In phase II trial ibudilast has exhibited efficacy in slowing down brain atrophy in patients with progressive MS [99].

**Antioxidants and agents improving mitochondrial function**

Disruption of energy production and dysfunction of mitochondria has been already implied as a contributing factor for neurodegeneration which takes place in MS. Increased demand for ATP in demyelinated axons with insufficient production of ATP by mitochondria can lead to intracellular sodium accumulation and secondary influx of calcium ions that promotes cell death [100-102]. Biotin is essential for energy homeostasis as it functions as a co-factor for essential enzymes catalysing carboxylation. These are involved in lipid synthesis, amino acid metabolism and Krebs cycle. Administration of high oral doses has slowed and, in some cases, reversed disability progression in patients with progressive MS. Beneficial effect on visual acuity has been reported in MS patients with progressive optic neuropathy. It probably promotes remyelination and mitochondrial energy production [103-105]. Biotin-dependent acetyl-CoA carboxylase catalyses the synthesis of malonyl-CoA, a substrate for production of fatty acids and thus, promotes myelin deposition. Furthermore, it may provide substrates for the Krebs cycle and raise levels of intracellular ATP.

Idebenone, an ubiquinone analogue, also functions as an electron carrier in oxidative phosphorylation. Trials with this agent gave positive but disputable results in Leber’s hereditary optic neuropathy [106] and Friedreich’s ataxia, genetic diseases where mitochondrial dysfunction has been reported [107-108]. The antioxidant has been explored as a neuroprotectant in EAE, although recent studies have yielded unfavorable results. Nevertheless, idebenone has been investigated as a treatment for MS [109].

Another free radical scavenger, MitoQ consists of triphenylphosphonium lipophilic cation attached to an alkyl chain linked with ubiquinone that enables it to be efficiently up-taken by mitochondria. It exerts its antioxidative effects by aiding mitochondrial function [110]. Administration has been protective against neuroinflammation and axonal degeneration in mice with induced EAE.

Alpha-lipoic acid, a natural molecule, has also potent antioxidative effects [111]. This endogenous molecule exerts neuroprotection via regeneration of glutathione pool, neutralization of free radicals and aids oxidative phosphorylation as a co-factor of pyruvate dehydrogenase. Interestingly, it also inhibits leukocyte migration to the CNS. Alpha-lipoic acid has reduced MMP-9 and sI-CAM concentrations with positive effects on blood-brain barrier integrity and reduction of brain atrophy in a small cohort of SPMS patients [112-113].

**Neuroprotective agents with other modes of action**

Simvastatin, the statin noted for its protective effects on vasculature, has pleiotropic effects aside from suppression of cholesterol synthesis. It is also known for its immunomodulatory effects [114]. It has been investigated in SPMS as a disease-modifying drug in MS-STAT study. Improvement on the quality of life and cognition in patients receiving high-dose simvastatin has been reported and the rate of brain atrophy has been reduced [115-116]. These neuroprotective effects could be explained by a combination of positive effects on cerebral blood flow and anti-oxidative properties [117-118]. Further trials are needed to assess feasibility of simvastatin in MS.

Siponimod, closely related to fingolimod, is another immunomodulatory agent. It has a similar mode of action as it affects recirculation of lymphocytes from the lymph nodes. It improves over fingolimod as it is more selective towards S1P and SSP receptors. It has been shown to slow disability progression. Siponimod administration resulted in a reduction of brain atrophy in individuals with SPMS suggesting neuroprotective effects exerted by modulation of S1P and SSP receptors that may mediate brain cell survival. Adverse reactions are similar to fingolimod [119-120].

The role of glycogen synthase kinase-3 (GSK-3) is suggested in immune response regulation [121]. Lithium, a treatment for bi-polar disorder, suppresses the function of the enzyme and has caused prevention of EAE onset and disease amelioration [122]. A trial in progressive MS has been performed to study effects on brain atrophy and evaluate lithium’s neuroprotective effects [123].

**Gut microbiome modification**

A complex community of microorganisms that inhabit the gastrointestinal tract is often referred to as the gut microbiome. Its influence on the nervous system has been more highlighted recently as it exerts its effects through immunological, endocrine and direct neural mechanisms [124]. The metabolites produced by intestinal bacteria such as short-chain fatty acids (SCFAs), sustain blood-brain barrier integrity, induce T-reg populations and regulate function of microglia in
the CNS. Polisaccharide-A, a metabolite of Bacteroides fragilis, has been reported as an immunomodulatory factor. Furthermore, stress-mediated hypothalamic-pituitary axis activation can lead to changes in intestinal barrier permeability and dysbiosis through actions of glucocorticosteroids and catecholamines. Involvement of neural pathways between the digestive tract and the CNS is important. Bacteria in the gut may interact with afferent neural fibers by producing neurotransmitters and directly stimulate them with their molecular patterns. In addition, stimulation of efferent signaling nerves can regulate immune cell activity [125]. The role of this gut-brain axis has been implied in pathophysiology of psychiatric and neurological disorders such as MS [126].

Immunomodulatory effects caused by microbiome modification either by antibiotic treatment or probiotics can be supported by evidence from animal models [127-129]. In one study, the incidence of EAE was higher in genetically prone mice with gut microbiome transplanted from MS affected subjects [130]. There are also hints that people with MS have a distinct composition of gut flora [131]. Moreover, besides blood-brain barrier, the intestinal barrier is also disrupted in many patients with MS and it may contribute to pathology of the disease. Gut flora can affect bile acid composition and vice-versa. Thus, strategies to modify the gut microbiome have been formulated. Trials in EAE in which probiotics were used have shown efficacy [132]. There is a possibility that such microbiological interventions could be translated to patients with MS as there are results from human studies that support such approaches. For example, there are ongoing trials with fecal microbial transplantation (FMT) [133-135]. Therapeutical infestation with helminths has been also explored, because parasites are known to skew immune response towards Th2 subtype, thus in effect ameliorating neuroinflammation [136-138].

Conclusions

Currently there is a variety of treatments available for patients with multiple sclerosis and this number is rising. They can be divided into symptomatic drugs (used in the setting of a relapse, e.g. glucocorticoids and IVIG) and disease-modifying drugs (DMD) that aim to influence long-term progression of the disease. None of aforementioned therapies are fully curative and most of them affect relapsing-remitting forms of the disease. Search for more specific therapies is ongoing that either try to reestablish self-tolerance, concentrate on regeneration and neuroprotection or modulate innate immune responses that are prominent in later stages of the disease and therefore promise a safer and hopefully more effective treatment in the future.

Conflicts of interest

None.


44. An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis. Clinical Trials Identifier: NCT01803867 [Internet]. [cited 2019 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01803867

45. An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse. ClinicalTrials.gov Identifier: NCT02398461 [Internet]. [cited 2019 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/ NCT02398461


54. Daniel Kantor, MD. Update on CHANGE-MS: Clinical Trial Results for GNbAC1. Is the cause of MS within us? [Internet]. 2018 june [cited 2019 Mar 14]. Available from: https://practicalneurology.com/articles/2018-june/update-on-change-ms-clinical-trial-results-for-gnbac1


64. Silk M, Nantz E. Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study (P3.397). Neurology [Internet]. 2018;90(15 Supplement):P3.397. Available from: http://nn.neurology.org/content/90/15_Supplement/P3.397.abstract


90. A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo. ClinicalTrials.g [Internet]. [cited 2019 Mar 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02284568


